Trials / Unknown
UnknownNCT02134054
Stavanger IBD Study - Cross Sectional
Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 210 (actual)
- Sponsor
- Helse Stavanger HF · Other Government
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
In this cross sectional and longitudinal study, patients with inflammatory bowel disease on biological treatment with infliximab or adalimumab will be included. After inclusion, the dosage of their existing biological therapy will be adjusted following regular trough-level and antibody-level monitoring, according to a treatment algorithm. Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis is that therapeutic drug monitoring may improve clinical disease outcome after one year of follow-up.
Conditions
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-11-01
- Completion
- 2024-12-01
- First posted
- 2014-05-08
- Last updated
- 2024-03-15
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT02134054. Inclusion in this directory is not an endorsement.